Phase I–II trial of weekly gemcitabine plus high‐dose 5‐fluorouracil and leucovorin in advanced pancreatic cancer

Background: Pancreatic cancer is a dismal disease. Few drugs, including gemcitabine and 5‐fluorouracil (5‐FU), have notable antitumor effects against advanced pancreatic cancer. The purpose of the present study was to determine the maximum tolerated dose (MTD) of 5‐FU and the efficacy and toxicity profile of weekly gemcitabine plus infusional 5‐FU/leucovorin in advanced pancreatic cancer. Methods: Patients with histo‐/cytologically confirmed,...